The company has received a national license to market the product in Portugal for two indications: to prevent Rh0(D) immunization women that are in Rh0(D) negative, and to treat Rh0(D) negative patients after incompatible Rh0(D) positive blood transfusions or other products containing erythrocytes antigens.
John A. Sedor, Cangene's president and chief executive officer, said: "Today's approval is a milestone for Cangene and significant news for expectant mothers and other Rh-negative patients in Portugal. By bringing WinRho to Portugal, we have reestablished a foothold in Europe as we drive the growth of Cangene's flagship product in markets outside of North America."
The product will be distributed nationally in Portugal by a third party distributor on behalf of Cangene.
Cangene's contract manufacturing group will be at table #140 at Contract Pharma's Contracting & Outsourcing Conference & Tabletop Exhibition on Sept. 19! For more information, visit the conference site!